// Immunology/Rheumatology - Drugs
// Auto-generated from modularize-data.js

const drugs = [
    {
        "id": "methotrexate",
        "name": "Methotrexate",
        "pharmacologicClass": "disease-modifying-antirheumatic-drugs-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Various mechanisms to suppress immune system and slow disease progression.",
        "features": "Folate analog, requires folate supplementation.",
        "clinicalChoice": "First-line DMARD for RA.",
        "indications": [
            "Rheumatoid Arthritis",
            "Psoriatic Arthritis",
            "Crohn Disease"
        ],
        "contraindications": [
            "Pregnancy",
            "Severe Renal/Hepatic Impairment"
        ],
        "sideEffects": [
            "Immunosuppression",
            "Hepatotoxicity",
            "Myelosuppression"
        ],
        "interactions": "Live vaccines contraindicated, increased infection risk.",
        "interactionDetails": "LIVE VACCINES: MECHANISM - DMARDs suppress immune system function, reducing ability to mount adequate immune response. CONSEQUENCE - Risk of disseminated infection from live vaccines, potentially fatal. Use killed vaccines only.",
        "pageType": "drug"
    },
    {
        "id": "sulfasalazine",
        "name": "Sulfasalazine",
        "pharmacologicClass": "disease-modifying-antirheumatic-drugs-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Various mechanisms to suppress immune system and slow disease progression.",
        "features": "Anti-inflammatory and immunosuppressive.",
        "clinicalChoice": "RA, inflammatory bowel disease.",
        "indications": [
            "Rheumatoid Arthritis",
            "Ulcerative Colitis"
        ],
        "contraindications": [
            "Sulfonamide Allergy",
            "G6PD Deficiency"
        ],
        "sideEffects": [
            "Immunosuppression",
            "Hepatotoxicity",
            "Myelosuppression"
        ],
        "interactions": "Live vaccines contraindicated, increased infection risk.",
        "interactionDetails": "LIVE VACCINES: MECHANISM - DMARDs suppress immune system function, reducing ability to mount adequate immune response. CONSEQUENCE - Risk of disseminated infection from live vaccines, potentially fatal. Use killed vaccines only.",
        "pageType": "drug"
    },
    {
        "id": "hydroxychloroquine",
        "name": "Hydroxychloroquine",
        "pharmacologicClass": "disease-modifying-antirheumatic-drugs-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Various mechanisms to suppress immune system and slow disease progression.",
        "features": "Antimalarial with anti-inflammatory effects.",
        "clinicalChoice": "Mild RA, SLE, malaria prophylaxis.",
        "indications": [
            "Rheumatoid Arthritis",
            "SLE",
            "Malaria"
        ],
        "contraindications": [
            "Retinal Disease",
            "G6PD Deficiency"
        ],
        "sideEffects": [
            "Immunosuppression",
            "Hepatotoxicity",
            "Myelosuppression"
        ],
        "interactions": "Live vaccines contraindicated, increased infection risk.",
        "interactionDetails": "LIVE VACCINES: MECHANISM - DMARDs suppress immune system function, reducing ability to mount adequate immune response. CONSEQUENCE - Risk of disseminated infection from live vaccines, potentially fatal. Use killed vaccines only.",
        "pageType": "drug"
    },
    {
        "id": "adalimumab",
        "name": "Adalimumab",
        "pharmacologicClass": "biologic-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Target specific inflammatory mediators (TNF-α, IL-1, IL-6).",
        "features": "TNF-α inhibitor, subcutaneous injection.",
        "clinicalChoice": "RA, psoriatic arthritis, IBD.",
        "indications": [
            "Rheumatoid Arthritis",
            "Psoriatic Arthritis",
            "Crohn Disease"
        ],
        "contraindications": [
            "Active Infection",
            "Latent TB"
        ],
        "sideEffects": [
            "Increased infection risk",
            "Injection site reactions",
            "Reactivation of TB"
        ],
        "interactions": "Live vaccines, other immunosuppressants.",
        "interactionDetails": "OTHER IMMUNOSUPPRESSANTS: MECHANISM - Additive immunosuppressive effects when combined with conventional DMARDs or corticosteroids. CONSEQUENCE - Significantly increased risk of opportunistic infections including PCP, TB reactivation, and fungal infections.",
        "pageType": "drug"
    },
    {
        "id": "infliximab",
        "name": "Infliximab",
        "pharmacologicClass": "biologic-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Target specific inflammatory mediators (TNF-α, IL-1, IL-6).",
        "features": "Chimeric monoclonal antibody against TNF-α.",
        "clinicalChoice": "Crohn disease, ulcerative colitis, rheumatoid arthritis.",
        "indications": [
            "Crohn Disease",
            "Ulcerative Colitis",
            "Rheumatoid Arthritis"
        ],
        "contraindications": [
            "Active Infection",
            "Latent TB"
        ],
        "sideEffects": [
            "Increased infection risk",
            "Injection site reactions",
            "Reactivation of TB"
        ],
        "interactions": "Live vaccines, other immunosuppressants.",
        "interactionDetails": "OTHER IMMUNOSUPPRESSANTS: MECHANISM - Additive immunosuppressive effects when combined with conventional DMARDs or corticosteroids. CONSEQUENCE - Significantly increased risk of opportunistic infections including PCP, TB reactivation, and fungal infections.",
        "pageType": "drug"
    },
    {
        "id": "etanercept",
        "name": "Etanercept",
        "pharmacologicClass": "biologic-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Target specific inflammatory mediators (TNF-α, IL-1, IL-6).",
        "features": "TNF receptor fusion protein.",
        "clinicalChoice": "Rheumatoid arthritis refractory to methotrexate.",
        "indications": [
            "Rheumatoid Arthritis",
            "Psoriatic Arthritis"
        ],
        "contraindications": [
            "Active Infection",
            "Latent TB"
        ],
        "sideEffects": [
            "Increased infection risk",
            "Injection site reactions",
            "Reactivation of TB"
        ],
        "interactions": "Live vaccines, other immunosuppressants.",
        "interactionDetails": "OTHER IMMUNOSUPPRESSANTS: MECHANISM - Additive immunosuppressive effects when combined with conventional DMARDs or corticosteroids. CONSEQUENCE - Significantly increased risk of opportunistic infections including PCP, TB reactivation, and fungal infections.",
        "pageType": "drug"
    },
    {
        "id": "rituximab",
        "name": "Rituximab",
        "pharmacologicClass": "biologic-dmards",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Target specific inflammatory mediators (TNF-α, IL-1, IL-6).",
        "features": "Anti-CD20, depletes B cells.",
        "clinicalChoice": "RA refractory to TNF inhibitors.",
        "indications": [
            "Rheumatoid Arthritis",
            "Non-Hodgkin Lymphoma"
        ],
        "contraindications": [
            "Active Infection",
            "Severe Heart Failure"
        ],
        "sideEffects": [
            "Increased infection risk",
            "Injection site reactions",
            "Reactivation of TB"
        ],
        "interactions": "Live vaccines, other immunosuppressants.",
        "interactionDetails": "OTHER IMMUNOSUPPRESSANTS: MECHANISM - Additive immunosuppressive effects when combined with conventional DMARDs or corticosteroids. CONSEQUENCE - Significantly increased risk of opportunistic infections including PCP, TB reactivation, and fungal infections.",
        "pageType": "drug"
    },
    {
        "id": "cyclosporine",
        "name": "Cyclosporine",
        "pharmacologicClass": "calcineurin-inhibitors",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Inhibit calcineurin to block IL-2 transcription and T-cell activation.",
        "features": "Binds cyclophilin.",
        "clinicalChoice": "Transplant rejection prophylaxis, severe psoriasis.",
        "indications": [
            "Organ Transplantation",
            "Psoriasis"
        ],
        "contraindications": [
            "Uncontrolled Hypertension",
            "Renal Dysfunction"
        ],
        "sideEffects": [
            "Nephrotoxicity",
            "Hypertension",
            "Neurotoxicity",
            "Gingival hyperplasia (cyclosporine)"
        ],
        "interactions": "CYP3A4 inhibitors markedly increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "tacrolimus",
        "name": "Tacrolimus",
        "pharmacologicClass": "calcineurin-inhibitors",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Inhibit calcineurin to block IL-2 transcription and T-cell activation.",
        "features": "Binds FKBP-12, more potent.",
        "clinicalChoice": "Solid organ transplant prophylaxis.",
        "indications": [
            "Organ Transplantation"
        ],
        "contraindications": [
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "Nephrotoxicity",
            "Hypertension",
            "Neurotoxicity",
            "Gingival hyperplasia (cyclosporine)"
        ],
        "interactions": "CYP3A4 inhibitors markedly increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "mycophenolate-mofetil",
        "name": "Mycophenolate Mofetil",
        "pharmacologicClass": "antimetabolite-immunosuppressants",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Inhibit nucleotide synthesis to prevent lymphocyte proliferation.",
        "features": "Inhibits IMP dehydrogenase in lymphocytes.",
        "clinicalChoice": "Transplant rejection prophylaxis, lupus nephritis.",
        "indications": [
            "Organ Transplantation",
            "Lupus Nephritis"
        ],
        "contraindications": [
            "Pregnancy"
        ],
        "sideEffects": [
            "Myelosuppression",
            "GI upset",
            "Hepatotoxicity"
        ],
        "interactions": "Allopurinol increases azathioprine toxicity; antacids reduce mycophenolate absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "azathioprine",
        "name": "Azathioprine",
        "pharmacologicClass": "antimetabolite-immunosuppressants",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Inhibit nucleotide synthesis to prevent lymphocyte proliferation.",
        "features": "Prodrug of 6-mercaptopurine.",
        "clinicalChoice": "Steroid-sparing agent for autoimmune disease.",
        "indications": [
            "Rheumatoid Arthritis",
            "Inflammatory Bowel Disease"
        ],
        "contraindications": [
            "Thiopurine Methyltransferase Deficiency"
        ],
        "sideEffects": [
            "Myelosuppression",
            "GI upset",
            "Hepatotoxicity"
        ],
        "interactions": "Allopurinol increases azathioprine toxicity; antacids reduce mycophenolate absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "sirolimus-rapamycin",
        "name": "Sirolimus (Rapamycin)",
        "pharmacologicClass": "mtor-inhibitors",
        "therapeuticClass": "immunosuppressants",
        "system": "immunology-rheumatology",
        "mechanism": "Block mTOR signaling downstream of IL-2 to prevent T-cell proliferation.",
        "features": "Used with calcineurin inhibitors to prevent chronic rejection.",
        "clinicalChoice": "Renal transplant immunosuppression.",
        "indications": [
            "Renal Transplantation"
        ],
        "contraindications": [
            "Severe Hepatic Impairment"
        ],
        "sideEffects": [
            "Hyperlipidemia",
            "Bone marrow suppression",
            "Mouth ulcers"
        ],
        "interactions": "CYP3A4 and P-gp substrates.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "prednisone",
        "name": "Prednisone",
        "pharmacologicClass": "systemic-corticosteroids",
        "therapeuticClass": "corticosteroids",
        "system": "immunology-rheumatology",
        "mechanism": "Bind glucocorticoid receptors, suppress inflammatory gene transcription.",
        "features": "Oral, intermediate-acting.",
        "clinicalChoice": "Inflammatory conditions, immunosuppression.",
        "indications": [
            "Rheumatoid Arthritis",
            "Asthma",
            "Allergic Reactions"
        ],
        "contraindications": [
            "Systemic Fungal Infections"
        ],
        "sideEffects": [
            "Osteoporosis",
            "Diabetes",
            "Infection risk",
            "Adrenal suppression"
        ],
        "interactions": "CYP3A4 inducers reduce efficacy, live vaccines.",
        "interactionDetails": "CYP3A4 INDUCERS: MECHANISM - Rifampin, phenytoin increase cortisol metabolism, reducing therapeutic levels. CONSEQUENCE - Loss of anti-inflammatory efficacy, potential disease flare. May need dose adjustment.",
        "pageType": "drug"
    },
    {
        "id": "methylprednisolone",
        "name": "Methylprednisolone",
        "pharmacologicClass": "systemic-corticosteroids",
        "therapeuticClass": "corticosteroids",
        "system": "immunology-rheumatology",
        "mechanism": "Bind glucocorticoid receptors, suppress inflammatory gene transcription.",
        "features": "IV/PO, more potent than prednisone.",
        "clinicalChoice": "Acute inflammatory conditions.",
        "indications": [
            "Severe Asthma",
            "Acute MS Relapse"
        ],
        "contraindications": [
            "Systemic Fungal Infections"
        ],
        "sideEffects": [
            "Osteoporosis",
            "Diabetes",
            "Infection risk",
            "Adrenal suppression"
        ],
        "interactions": "CYP3A4 inducers reduce efficacy, live vaccines.",
        "interactionDetails": "CYP3A4 INDUCERS: MECHANISM - Rifampin, phenytoin increase cortisol metabolism, reducing therapeutic levels. CONSEQUENCE - Loss of anti-inflammatory efficacy, potential disease flare. May need dose adjustment.",
        "pageType": "drug"
    },
    {
        "id": "dexamethasone",
        "name": "Dexamethasone",
        "pharmacologicClass": "systemic-corticosteroids",
        "therapeuticClass": "corticosteroids",
        "system": "immunology-rheumatology",
        "mechanism": "Bind glucocorticoid receptors, suppress inflammatory gene transcription.",
        "features": "Long-acting, potent, minimal mineralocorticoid activity.",
        "clinicalChoice": "Cerebral edema, high-altitude sickness.",
        "indications": [
            "Cerebral Edema",
            "Adrenal Insufficiency Testing"
        ],
        "contraindications": [
            "Systemic Fungal Infections"
        ],
        "sideEffects": [
            "Osteoporosis",
            "Diabetes",
            "Infection risk",
            "Adrenal suppression"
        ],
        "interactions": "CYP3A4 inducers reduce efficacy, live vaccines.",
        "interactionDetails": "CYP3A4 INDUCERS: MECHANISM - Rifampin, phenytoin increase cortisol metabolism, reducing therapeutic levels. CONSEQUENCE - Loss of anti-inflammatory efficacy, potential disease flare. May need dose adjustment.",
        "pageType": "drug"
    },
    {
        "id": "allopurinol",
        "name": "Allopurinol",
        "pharmacologicClass": "uric-acid-lowering-agents",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Reduce uric acid production (allopurinol) or increase excretion (probenecid).",
        "features": "Xanthine oxidase inhibitor.",
        "clinicalChoice": "Chronic gout prevention, tumor lysis syndrome.",
        "indications": [
            "Chronic Gout",
            "Hyperuricemia",
            "Tumor Lysis Syndrome"
        ],
        "contraindications": [
            "Acute Gout Attack",
            "HLA-B*5801 (Asians)"
        ],
        "sideEffects": [
            "Gout flares initially",
            "Hypersensitivity reactions",
            "Kidney stones"
        ],
        "interactions": "Azathioprine with allopurinol (severe toxicity).",
        "interactionDetails": "AZATHIOPRINE: MECHANISM - Allopurinol inhibits xanthine oxidase, which metabolizes azathioprine. This leads to accumulation of toxic metabolites. CONSEQUENCE - Severe myelosuppression and life-threatening bone marrow toxicity requiring dose reduction.",
        "pageType": "drug"
    },
    {
        "id": "probenecid",
        "name": "Probenecid",
        "pharmacologicClass": "uric-acid-lowering-agents",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Reduce uric acid production (allopurinol) or increase excretion (probenecid).",
        "features": "Uricosuric agent, blocks renal reabsorption.",
        "clinicalChoice": "Gout in patients with normal kidney function.",
        "indications": [
            "Chronic Gout"
        ],
        "contraindications": [
            "Kidney Stones",
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "Gout flares initially",
            "Hypersensitivity reactions",
            "Kidney stones"
        ],
        "interactions": "Azathioprine with allopurinol (severe toxicity).",
        "interactionDetails": "AZATHIOPRINE: MECHANISM - Allopurinol inhibits xanthine oxidase, which metabolizes azathioprine. This leads to accumulation of toxic metabolites. CONSEQUENCE - Severe myelosuppression and life-threatening bone marrow toxicity requiring dose reduction.",
        "pageType": "drug"
    },
    {
        "id": "colchicine",
        "name": "Colchicine",
        "pharmacologicClass": "acute-gout-treatment",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Anti-inflammatory effects to treat acute gout attacks.",
        "features": "Microtubule inhibitor, anti-inflammatory.",
        "clinicalChoice": "Acute gout attacks, familial Mediterranean fever.",
        "indications": [
            "Acute Gout",
            "Familial Mediterranean Fever"
        ],
        "contraindications": [
            "Severe Renal/Hepatic Impairment"
        ],
        "sideEffects": [
            "GI upset",
            "Diarrhea",
            "Neutropenia"
        ],
        "interactions": "CYP3A4 inhibitors increase colchicine toxicity.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "indomethacin",
        "name": "Indomethacin",
        "pharmacologicClass": "acute-gout-treatment",
        "therapeuticClass": "gout-medications",
        "system": "immunology-rheumatology",
        "mechanism": "Anti-inflammatory effects to treat acute gout attacks.",
        "features": "Potent NSAID.",
        "clinicalChoice": "Acute gout when colchicine contraindicated.",
        "indications": [
            "Acute Gout",
            "Patent Ductus Arteriosus"
        ],
        "contraindications": [
            "Peptic Ulcer Disease",
            "Severe Heart Failure"
        ],
        "sideEffects": [
            "GI upset",
            "Diarrhea",
            "Neutropenia"
        ],
        "interactions": "CYP3A4 inhibitors increase colchicine toxicity.",
        "interactionDetails": "",
        "pageType": "drug"
    }
];

export default drugs;
